DoubleChecks

What was claimed

NEW STUDY: 84.4% Of Cancer Patients Taking Ivermectin & Mebendazole Had Their Cancer Completely Disappear (with peer-reviewed PubMed claims)

Our verdict

Needs caution

The study reports an 84.4% clinical benefit ratio, not 84.4% complete disappearance. Only 32.8% reported no current evidence of disease, and the outcomes were self-reported. A PubMed-indexed paper exists, but its observational design and self-reported outcomes do not establish that the drugs caused cancer disappearance or prove efficacy.

1 of 3 AI systems agree15 sources citedChecked Aug 18, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

A peer‑reviewed PubMed study shows 84.4% of cancer patients taking ivermectin and mebendazole had their cancer completely disappear.

Incorrect97%
2 of 3 AIs agree·ChatGPT: Misleading

This represents definitive evidence of cancer treatment efficacy

Misleading92%
1 AI checked

The claim is supported by peer-reviewed PubMed evidence.

Misleading93%
1 of 2 AIs agree·Claude: Verified

48.4% of participants reported tumor regression or no evidence of disease.

Verified98%
1 AI checked

84.4% was the clinical benefit ratio in the study.

Verified99%
1 AI checked

Verified against 15 sources

pubmed.ncbi.nlm.nih.govx.comsgtreport.comsanarelab.scienceexplore.openaire.eux.comtwc.healthyoutube.comyoutube.comtherealfacthunter.comx.cominstagram.comyoutube.comfacebook.cominstagram.com

Detailed Analysis

The headline is misleading and overstates what the study showed. The cited paper reports an 84.4% clinical benefit ratio, not that 84.4% of patients had cancer completely disappear, and the outcomes were self-reported in an observational cohort without randomization or a control group.[1] [5] The study found 32.8% reported no current evidence of disease and 15.6% reported regression, but that does not support a claim of proven cancer cure or treatment efficacy.[1] [5]

Why this verdict

  • The headline is misleading and overstates what the study showed.
  • The cited paper reports an 84.4% clinical benefit ratio, not that 84.4% of patients had cancer completely disappear, and the outcomes were self-reported in an observational cohort without randomization or a control group.[1] [5] The study found 32.8% reported no current evidence of disease and 15.6% reported regression, but that does not support a claim of proven cancer cure or treatment efficacy.[1] [5]

Claims checked

84.4% of cancer patients taking ivermectin and mebendazole had their cancer completely disappear.

Incorrect98%
The study reports an 84.4% clinical benefit ratio, not 84.4% complete disappearance. Only 32.8% reported no current evidence of disease, and the outcomes were self-reported.[1] [5]

This claim may mislead readers without added context.

The claim is supported by peer-reviewed PubMed evidence.

Misleading93%
A PubMed-indexed paper exists, but its observational design and self-reported outcomes do not establish that the drugs caused cancer disappearance or prove efficacy.[1] [5]

This claim may mislead readers without added context.

48.4% of participants reported tumor regression or no evidence of disease.

Verified98%
The paper states that 48.4% reported either regression or no evidence of disease, with 32.8% NED and 15.6% regression.[1] [5]

What other AI think

The claim significantly misrepresents the study findings by stating 84.4% had "cancer completely disappear," when only 32.8% reported no evidence of disease. The 84.4% figure includes disease stabilization and tumor shrinkage, not complete disappearance. Additionally, the study is observational with self-reported outcomes and lacks randomized controlled trial validation.

Why this verdict

  • The claim significantly misrepresents the study findings by stating 84.4% had "cancer completely disappear," when only 32.8% reported no evidence of disease.
  • The 84.4% figure includes disease stabilization and tumor shrinkage, not complete disappearance.
  • Additionally, the study is observational with self-reported outcomes and lacks randomized controlled trial validation.

Claims checked

84.4% of cancer patients had their cancer completely disappear

Incorrect95%
Only 32.8% reported no evidence of disease. The 84.4% Clinical Benefit Ratio includes disease stabilization (36.1%) and tumor regression (15.6%), not complete disappearance.

This claim may mislead readers without added context.

This represents definitive evidence of cancer treatment efficacy

Misleading92%
The study is observational with self-reported outcomes and lacks randomized controlled trial validation. Authors explicitly state findings are 'hypothesis-generating' and call for RCTs to validate results.

This claim may mislead readers without added context.

The study is peer-reviewed and published in PubMed

Verified98%
The study was published in Anticancer Research journal and is available on PubMed (PMID: 42203321).
The published paper reports an 84.4% 'clinical benefit ratio' in a self‑reported, prospective observational cohort. The claim that 84.4% had their cancer "completely disappear" is a misleading summary of the paper's results and ignores major methodological and editorial concerns.

Why this verdict

  • The published paper reports an 84.4% 'clinical benefit ratio' in a self‑reported, prospective observational cohort.
  • The claim that 84.4% had their cancer "completely disappear" is a misleading summary of the paper's results and ignores major methodological and editorial concerns.

Claims checked

A peer‑reviewed PubMed study shows 84.4% of cancer patients taking ivermectin and mebendazole had their cancer completely disappear.

Misleading92%
The cited PubMed entry reports a Clinical Benefit Ratio of 84.4%, which combines 'no evidence of disease', 'regression' and 'stable disease', not 'complete disappearance' for 84.4% of patients; only ~32.8% were reported as 'no current evidence of disease'. The study is observational, largely self‑reported, and an Expression of Concern has been issued about data and ethical/validity issues.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks